119 related articles for article (PubMed ID: 36646142)
1. Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons.
Reacher M; Warne B; Verlander NQ; Popay A; Reeve L; Jones NK; Ranellou K; Sithole N; Carpenter R; Everden A; Jarman E; Khalid A; Lam K; Myers C; Ren S; Rolfe KJ; Sutton T; Christou S; Wright C; Choudhry S; Zambon M; Sander C; Zhang H; Jalal H
J Infect; 2023 Mar; 86(3):256-308. PubMed ID: 36646142
[TBL] [Abstract][Full Text] [Related]
2. Influenza-associated mortality in hospital care: a retrospective cohort study of risk factors and impact of oseltamivir in an English teaching hospital, 2016 to 2017.
Reacher M; Warne B; Reeve L; Verlander NQ; Jones NK; Ranellou K; Christou S; Wright C; Choudhry S; Zambon M; Sander C; Zhang H; Jalal H
Euro Surveill; 2019 Oct; 24(44):. PubMed ID: 31690364
[TBL] [Abstract][Full Text] [Related]
3. Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir.
Rath B; Chen X; Spies V; Muehlhans S; Obermeier P; Tief F; Seeber L; Karsch K; Milde J; Skopnik H; Schweiger B; Duwe SC
Antivir Ther; 2017; 22(6):515-522. PubMed ID: 28205506
[TBL] [Abstract][Full Text] [Related]
4. Influenza antiviral prescribing practices during the 2007-08 and 2008-09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses.
Dharan NJ; Beekmann SE; Fiore A; Finelli L; Uyeki TM; Polgreen PM; Fry AM
Antiviral Res; 2010 Nov; 88(2):182-6. PubMed ID: 20739002
[TBL] [Abstract][Full Text] [Related]
5. Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.
Chaudhry A; Bastien N; Li Y; Scott A; Pabbaraju K; Stewart D; Wong S; Drews SJ
Influenza Other Respir Viruses; 2016 Nov; 10(6):532-535. PubMed ID: 27442795
[TBL] [Abstract][Full Text] [Related]
6. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.
Stephenson I; Democratis J; Lackenby A; McNally T; Smith J; Pareek M; Ellis J; Bermingham A; Nicholson K; Zambon M
Clin Infect Dis; 2009 Feb; 48(4):389-96. PubMed ID: 19133796
[TBL] [Abstract][Full Text] [Related]
7. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
Sheu TG; Deyde VM; Okomo-Adhiambo M; Garten RJ; Xu X; Bright RA; Butler EN; Wallis TR; Klimov AI; Gubareva LV
Antimicrob Agents Chemother; 2008 Sep; 52(9):3284-92. PubMed ID: 18625765
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness of baloxavir marboxil against influenza in three seasons.
Kakuya F; Okubo H; Fujiyasu H; Kurisawa MJ; Kinebuchi T
Pediatr Int; 2022 Jan; 64(1):e15169. PubMed ID: 35790049
[TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
[TBL] [Abstract][Full Text] [Related]
11. Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
Trebbien R; Christiansen CB; Fischer TK
J Clin Virol; 2018 May; 102():1-6. PubMed ID: 29448067
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial.
Hung IFN; To KKW; Chan JFW; Cheng VCC; Liu KSH; Tam A; Chan TC; Zhang AJ; Li P; Wong TL; Zhang R; Cheung MKS; Leung W; Lau JYN; Fok M; Chen H; Chan KH; Yuen KY
Chest; 2017 May; 151(5):1069-1080. PubMed ID: 27884765
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of human H3N2 influenza virus to oseltamivir in South Korea, 2009-2011.
Park S; Kim JI; Lee I; Lee S; Hwang MW; Bae JY; Heo J; Lim EJ; Seok WS; Cheong HJ; Song JY; Kim WJ; Park MS
J Microbiol; 2012 Dec; 50(6):1067-70. PubMed ID: 23274998
[TBL] [Abstract][Full Text] [Related]
14. The effect of timing of oseltamivir chemoprophylaxis in controlling influenza A H3N2 outbreaks in long-term care facilities in Manitoba, Canada, 2014-2015: a retrospective cohort study.
Singh D; Jiang D; Van Caeseele P; Loeppky C
Infect Control Hosp Epidemiol; 2018 Aug; 39(8):955-960. PubMed ID: 29893659
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza season.
Tani N; Kawai N; Chong Y; Bando T; Iwaki N; Kashiwagi S; Ikematsu H
J Infect; 2022 Feb; 84(2):151-157. PubMed ID: 34861350
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.
Sugaya N; Tamura D; Yamazaki M; Ichikawa M; Kawakami C; Kawaoka Y; Mitamura K
Clin Infect Dis; 2008 Aug; 47(3):339-45. PubMed ID: 18582202
[TBL] [Abstract][Full Text] [Related]
17. Oseltamivir in influenza outbreaks in care homes: challenges and benefits of use in the real world.
Millership S; Cummins A
J Hosp Infect; 2015 Aug; 90(4):299-303. PubMed ID: 26071039
[TBL] [Abstract][Full Text] [Related]
18. Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
Kawai N; Ikematsu H; Kawashima T; Maeda T; Ukai H; Hirotsu N; Iwaki N; Kashiwagi S
Influenza Other Respir Viruses; 2013 May; 7(3):448-55. PubMed ID: 22897904
[TBL] [Abstract][Full Text] [Related]
19. Differences in antibiotic and antiviral use in people with confirmed influenza: a retrospective comparison of rapid influenza PCR and multiplex respiratory virus PCR tests.
Au Yeung V; Thapa K; Rawlinson W; Georgiou A; Post JJ; Overton K
BMC Infect Dis; 2021 Apr; 21(1):321. PubMed ID: 33827458
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction.
Sato M; Honzumi K; Sato T; Hashimoto K; Watanabe M; Miyazaki K; Kawasaki Y; Hosoya M
J Clin Virol; 2015 Jul; 68():97-103. PubMed ID: 26071346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
